MRKR Marker Therapeutics Inc.

5.51
+0.05  (+1%)
Previous Close 5.46
Open 5.48
Price To Book 4.21
Market Cap 250378279
Shares 45,440,704
Volume 261,051
Short Ratio
Av. Daily Volume 405,942

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due by the end of 2019.
TPIV200
Platinum-sensitive ovarian cancer
26/27 patients have shown immune response.
TPIV200
Second line triple-negative breast cancer (TNBC)
Phase 2 trial to be initiated later in 2019.
MultiTAA-Specific T Cells
Acute Lymphoblastic Leukemia
Phase 1/2 data presented at ASH 2018.
MultiTAA-Specific T Cells
Multiple Myeloma
Phase 1/2 trial ongoing.
MultiTAA-Specific T Cells
Lymphoma
Phase 1 updated data released February 25, 2019. 9/13 CRs 6 weeks to 2.5 years post-infusion.
MultiTAA-Specific T Cells
Acute Myeloid Leukemia
Phase 1/2 data due 3Q 2019.
MultiTAA-Specific T Cells
Pancreatic cancer

Latest News

  1. Here's Why Marker Therapeutics Fell as Much as 11.5% Today
  2. Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
  3. Marker Therapeutics Provides Business and Clinical Update
  4. These 5 Stocks Make Great Buys on New Analyst Coverage
  5. Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
  6. Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
  7. Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
  8. Marker Therapeutics to Present at the CAR-TCR Summit Europe
  9. Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility
  10. Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
  11. Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference
  12. Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?
  13. Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019
  14. The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
  15. Marker Therapeutics Provides Updates of its Lead Clinical Programs
  16. These 4 Healthcare Stocks May Test December Highs
  17. Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit
  18. The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
  19. Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
  20. Marker Therapeutics to Present at Three Upcoming Healthcare Conferences